Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer.
Saved in:
| Title: | Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer. |
|---|---|
| Authors: | Cohen, E. E. W.1 ecohen@ucsd.edu, Licitra, L. F.2,3, Burtness, B.4, Fayette, J.5,6, Gauler, T.7, Clement, P. M.8, Grau, J. J.9, del Campo, J. M.10, Mailliez, A.11, Haddad, R. I.12,13, Vermorken, J. B.14, Tahara, M.15, Guigay, J.16, Geoffrois, L.17, Merlano, M. C.18, Dupuis, N.19, Krämer, N.20, Cong, X. J.21, Gibson, N.22, Solca, F.23 |
| Source: | Annals of Oncology. Oct2017, Vol. 28 Issue 10, p2526-2532. 7p. 3 Charts. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
